BridgeBio Pharma Inc — Cash Flow (NASDAQ:BBIO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 399.71 M497.93 M419.49 M527.72 M520.73 M445.91 M 445.91 M Cash from investing activities 52.99 M200.83 M453.15 M54.03 M60.78 M24.49 M 24.49 M Cash from financing activities 447.19 M736.45 M13.13 M451.54 M748.46 M359.29 M 359.29 M Free cash flow 392.2 M449.69 M413.17 M526.41 M511.82 M436.32 M 436.32 M

News

Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS)

BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates

BridgeBio rises on revenue beat despite wider loss

BridgeBio Pharma earnings missed by $0.28, revenue topped estimates

Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio? - BridgeBio Pharma (NASDAQ:BBIO), BorgWarner (NYSE:BWA), Expedia Group (NASDAQ:EXPE), Flutter Entertainment (NYSE:FLUT)

Bausch Health (BHC) Q4 Earnings Lag Estimates

BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock

BridgeBio Pharma director Scott sells $754k in BBIO stock

BridgeBio earnings up next: Can pipeline wins fuel growth?

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline

Allspring Growth Fund Q4 2025 Fund Performers And Detractors

BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript